HKA Block Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders associated with acid reflux and motility disturbances. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by accelerating gastric emptying and improving esophageal sphincter tone, thereby reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The sustained-release (SR) formulation of HKA Block Capsule ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and symptom control. This combination is particularly beneficial in patients requiring both acid suppression and prokinetic effects to alleviate complex upper gastrointestinal symptoms. HKA Block Capsule SR should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, underlying cardiac conditions, or concurrent use of medications that may interact adversely. Regular monitoring and adherence to prescribed dosage are essential to optimize therapeutic outcomes and minimize potential adverse effects.